The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that FDA Peptide Reclassification 2026: What It Actually Means FDA Peptide Ban Lifted: Legit Compounding Pharmacies Now Regulate Julian Becerra posted on the topic LinkedIn GHK Cu [50mg] Elixser Peptides FDA Peptide Reclassification 2026: What It Means for Providers The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what